Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
Lokavant provides clinical trial intelligence
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Subscribe To Our Newsletter & Stay Updated